ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,501,468 | -8.8% | 202,707 | +3.3% | 0.02% | 0.0% |
| Q2 2023 | $6,030,051 | -10.5% | 196,163 | +4.9% | 0.02% | -15.0% |
| Q1 2023 | $6,739,880 | -19.4% | 187,063 | -11.6% | 0.02% | -25.9% |
| Q4 2022 | $8,366,226 | -10.6% | 211,696 | -9.1% | 0.03% | -10.0% |
| Q3 2022 | $9,361,000 | -19.8% | 232,985 | -16.1% | 0.03% | -3.2% |
| Q2 2022 | $11,679,000 | +20.2% | 277,808 | +11.4% | 0.03% | +55.0% |
| Q1 2022 | $9,714,000 | +40.0% | 249,333 | +43.1% | 0.02% | +53.8% |
| Q4 2021 | $6,941,000 | +71.6% | 174,187 | +55.6% | 0.01% | +62.5% |
| Q3 2021 | $4,046,000 | -5.7% | 111,965 | +7.0% | 0.01% | -11.1% |
| Q2 2021 | $4,289,000 | -9.0% | 104,624 | -3.2% | 0.01% | -10.0% |
| Q1 2021 | $4,713,000 | +74.8% | 108,042 | +100.6% | 0.01% | +66.7% |
| Q4 2020 | $2,696,000 | +461.7% | 53,870 | +371.7% | 0.01% | +500.0% |
| Q3 2020 | $480,000 | – | 11,420 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |